Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SPTX with free AI briefings, catalyst countdowns, and dilution alerts.

SPTX · Seaport Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$290.4M Cash on Hand
35.7mo Cash Runway
7.3% Short Interest
$37.12 Analyst Target (8)
Follow SPTX by email Get an email when SPTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SPTX, unsubscribe in one click. Privacy

📣 What SPTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
SPT-300 Major Depressive Disorder (MDD) Phase 2 · NCT07065240 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SPTX holds $290.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.4M/quarter from operations, an estimated runway of 35.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SPTX files for a raise →

👥 Who Owns SPTX

Insiders 68.2% Other 5%+ holders 11.8% Institutions (87 holders) 20% Public and other holders 0%
HolderTypeShares% of sharesAs of
PureTech Health plc
10% owner
Insider 16,685,013 31.17% 2026-06-30
ARCH Venture Partners XII, LLC
10% owner
Insider 6,294,951 11.76% 2026-05-04
ARCH Venture Fund XII, L.P. 5%+ holder (13D) 6,294,951 11.76% 2026-05-04
Arch Venture Management, Llc Institution (13F) 6,294,951 11.76% 2026-09-30
General Atlantic (SP), L.P.
Director, 10% owner
Insider 6,101,582 11.40% 2026-05-04
GAP Coinvestments CDA, L.P.
Director, 10% owner
Includes shares also reported by General Atlantic (SP), L.P., counted once
Insider 6,101,582 11.40% 2026-05-04
General Atlantic, L.P. Institution (13G, 5%+) 6,101,582 11.40% 2026-05-04
Sofinnova Investments, Inc. Institution (13F) 3,564,871 6.66% 2026-09-30
Steven M Paul
Director · +991,192 options
Insider 3,516,718 6.57% 2026-06-30
THE GOLDMAN SACHS GROUP, INC. Institution (13G, 5%+) 2,791,814 5.22% 2026-05-06
James Healy
Director
Insider 2,731,538 5.10% 2026-05-04
Trv Gp VI, LLC Institution (13F) 2,061,222 3.85% 2026-09-30

Share count 53,530,550 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-10
filed 2026-11-13
Zohar Daphne
Gift (G) 100,000 – 1,094,001
2026-11-03
filed 2026-11-04
Torres Denice
Purchase (P) 5,000 $19.87 5,000
2026-06-22
filed 2026-06-24
HOMBACH ROBERT J.
Purchase (P) 13,000 $18.14 13,000
2026-05-04
filed 2026-05-06
PureTech Health plc
Conversion (C) 3,031,578 – –
2026-05-04
filed 2026-05-06
PureTech Health plc
Conversion (C) 12,736,014 – 13,038,493

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full SPTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SPTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.